Cargando…

cGAS-STING pathway expression as a prognostic tool in NSCLC

BACKGROUND: Disease recurrence in localized lung adenocarcinoma is a major obstacle for improving the overall outcome of lung cancer. Thus, better prognostic biomarkers are needed to identify patients at risk. In order to clear cancer, immune detection of tumor cells is of vital importance. DNA-leak...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raaby Gammelgaard, Kristine, Sandfeld-Paulsen, Birgitte, Godsk, Stine Høvring, Demuth, Christina, Meldgaard, Peter, Sorensen, Boe Sandahl, Jakobsen, Martin Roelsgaard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867790/ https://www.ncbi.nlm.nih.gov/pubmed/33569317 http://dx.doi.org/10.21037/tlcr-20-524

Ejemplares similares

Increased PD-L1 expression in erlotinib-resistant NSCLC cells with MET gene amplification is reversed upon MET-TKI treatment
por: Demuth, Christina, et al.
Publicado: (2017)

Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors
por: Pedersen, Jesper Geert, et al.
Publicado: (2020)

Up-Regulated FGFR1 Expression as a Mediator of Intrinsic TKI Resistance in EGFR-Mutated NSCLC
por: Gammelgaard, Kristine Raaby, et al.
Publicado: (2018)

Neurofilament Light Chain as A Biomarker for Brain Metastases
por: Winther-Larsen, Anne, et al.
Publicado: (2020)

Epithelial-to-mesenchymal transition is a resistance mechanism to sequential MET-TKI treatment of MET-amplified EGFR-TKI resistant non-small cell lung cancer cells
por: Clement, Michelle Simone, et al.
Publicado: (2020)

IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells
por: Hussmann, Dianna, et al.
Publicado: (2017)

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment
por: Demuth, Christina, et al.
Publicado: (2018)

Gene Expression of the EGF System—a Prognostic Model in Non–Small Cell Lung Cancer Patients Without Activating EGFR Mutations()
por: Sandfeld-Paulsen, Birgitte, et al.
Publicado: (2016)

Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC
por: Ulhoi, Maiken Parm, et al.
Publicado: (2021)

The cGAS Paradox: Contrasting Roles for cGAS-STING Pathway in Chromosomal Instability
por: Hong, Christy, et al.
Publicado: (2019)

cGAS-STING pathway in cancer biotherapy
por: Wang, Yang, et al.
Publicado: (2020)

A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations
por: Demuth, Christina, et al.
Publicado: (2018)

Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2016)

cGAS-STING pathway in oncogenesis and cancer therapeutics
por: Hoong, Brandon Yi Da, et al.
Publicado: (2020)

Attenuation of cGAS/STING activity during mitosis
por: Uhlorn, Brittany L, et al.
Publicado: (2020)

The interactions between cGAS-STING pathway and pathogens
por: Cheng, Zhangliang, et al.
Publicado: (2020)

cGAS-STING, an important pathway in cancer immunotherapy
por: Jiang, Minlin, et al.
Publicado: (2020)

The Complexity of the cGAS-STING Pathway in CNS Pathologies
por: Fryer, Amelia L., et al.
Publicado: (2021)

The role of cGAS-STING signalling in liver diseases
por: Chen, Ruihan, et al.
Publicado: (2021)

cGAS/STING: novel perspectives of the classic pathway
por: Gao, Menghui, et al.
Publicado: (2020)

Advances in cGAS-STING Signaling Pathway and Diseases
por: Yang, Yuting, et al.
Publicado: (2022)

Mitotic inactivation of the cGAS‒MITA/STING pathways
por: Zhong, Li, et al.
Publicado: (2021)

Telomere Maintenance and the cGAS-STING Pathway in Cancer
por: Ebata, Hiroshi, et al.
Publicado: (2022)

Intercellular transmission of cGAS-STING signaling in cancer
por: Wu, Qirou, et al.
Publicado: (2023)

Role of cGAS–Sting Signaling in Alzheimer’s Disease
por: Govindarajulu, Manoj, et al.
Publicado: (2023)

The Activation of cGAS-STING in Acute Kidney Injury
por: Sun, Chuanchuan, et al.
Publicado: (2023)

Targeting the loss of cGAS/STING signaling in cancer
por: Sasaki, Nobunari, et al.
Publicado: (2023)

Significance of the cGAS-STING Pathway in Health and Disease
por: Zhou, Jinglin, et al.
Publicado: (2023)

cGAS-STING triggers inflammaging-associated neurodegeneration
por: Izquierdo, José M.
Publicado: (2023)

Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients()
por: Winther-Larsen, Anne, et al.
Publicado: (2016)

Chikungunya virus antagonizes cGAS-STING mediated type-I interferon responses by degrading cGAS
por: Webb, L. G., et al.
Publicado: (2020)

The cGAS-STING Defense Pathway and Its Counteraction by Viruses
por: Ma, Zhe, et al.
Publicado: (2016)

cGAS-independent STING activation in response to DNA damage
por: Unterholzner, Leonie, et al.
Publicado: (2019)

Conserved strategies for pathogen evasion of cGAS–STING immunity
por: Eaglesham, James B, et al.
Publicado: (2020)

The cGAS-STING Pathway in Hematopoiesis and Its Physiopathological Significance
por: Liao, Weinian, et al.
Publicado: (2020)

Activation of the cGAS–STING signaling pathway in adenomyosis patients
por: Lin, Yun, et al.
Publicado: (2021)

Activation of cGAS/STING pathway upon paramyxovirus infection
por: Iampietro, Mathieu, et al.
Publicado: (2021)

The Function of cGAS-STING Pathway in Treatment of Pancreatic Cancer
por: Mohseni, Ghazal, et al.
Publicado: (2021)

The cGAS-STING Pathway in Bacterial Infection and Bacterial Immunity
por: Liu, Nanxin, et al.
Publicado: (2022)

The cGAS-STING Pathway: Novel Perspectives in Liver Diseases
por: Xu, Dongwei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nn2l8m6gv0u1p48ujnf1oo13b5